CBZ-L-glutamine (CAS 2650-64-8, C₁₃H₁₆N₂O₅, M_r 280.28) is used as the N-protected carboxyl component in stepwise solution-phase synthesis of nonapeptide APIs of the oxytocin/vasopressin class. The Cbz group protects the α-amino function while the primary amide side chain of glutamine remains unprotected; therefore the coupling step is operated as a temperature-controlled mixed anhydride activation. A representative protocol begins with 1.00 eq CBZ-L-glutamine in anhydrous DMF or THF, cooled to −15 °C to −10 °C, followed by addition of 1.0–1.1 eq N-methylmorpholine and 1.0–1.05 eq isobutyl chloroformate. Activation is held for 10–15 min before the amine component is introduced. Prolonged activation beyond 20 min or internal temperature excursions above 0 °C increase the risk of dehydration of the unprotected Gln side chain to the corresponding nitrile. Process development groups track this impurity by HPLC; published numerical limits are campaign-specific, but a control point of NMT 0.15% area percent for the nitrile impurity is commonly applied in cGMP fragment manufacturing. After coupling, the organic phase is washed, concentrated, and the Cbz group is removed by catalytic hydrogenation over 5% or 10% palladium on carbon at 1–4 bar H₂ and 20–30 °C in methanol or methanol/water. The hydrogenation is performed in a Parr shaker-type pressure vessel or a jacketed glass pressure reactor with external cooling. The resulting N-terminal-free Gln-containing peptide fragment is isolated as acetate or hydrochloride salt and carried into the next fragment condensation. Residual palladium in the isolated intermediate is controlled to NMT 10 ppm according to ICH Q3D; residual solvents are controlled according to ICH Q3C. The terminal finished products are protected Gln-containing peptide fragments of the oxytocin/vasopressin family in which the glutamine residue is positioned at the C-terminal side of a newly formed amide bond.

How Does CBZ-L-Glutamine Enter Transglutaminase Donor Substrate Synthesis?

Tissue transglutaminase (TG2, EC 2.3.2.13) and factor XIIIa convert the carboxamide of peptide-bound glutamine into a reactive acyl-enzyme intermediate that is trapped by a primary amine. CBZ-L-glutamine is used to build N-blocked glutamine donor peptides such as Z-Gln-Gly, which serve as small-molecule substrates in transglutaminase activity assays. The condensation of CBZ-L-glutamine with glycine methyl ester hydrochloride typically uses carbodiimide-mediated activation in DMF or dichloromethane at 0–5 °C. A representative charge ratio is 1.00 eq CBZ-L-glutamine, 1.05 eq glycine methyl ester hydrochloride, 1.1 eq N-methylmorpholine, 1.1 eq 1-hydroxybenzotriazole monohydrate, and 1.05 eq 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride. The reaction mass is warmed to 20–25 °C and stirred for 12–18 h. The resulting Z-Gln-Gly methyl ester is then saponified with lithium hydroxide in tetrahydrofuran/water at 0–5 °C to obtain Z-Gln-Gly free acid. Because the product is a research-use enzyme substrate, release is typically by preparative HPLC with mass confirmation, and the final lyophilizate is stored at −20 °C under argon. Published enzyme kinetic parameters for CBZ-L-glutamine-derived transglutaminase substrates are assay-specific: TG2, factor XIIIa, and microbial transglutaminase differ in amine acceptor specificity and pH optima, so K_m and k_cat values cannot be transferred across isoforms without reference to the originating assay method. The terminal finished products include plate-reader transglutaminase activity kits and fluorogenic modifications of the glycine carboxyl by amine-reactive dyes.

Conversion of CBZ-L-glutamine to its N-hydroxysuccinimide or pentafluorophenyl esters is a standard downstream operation for peptide conjugate manufacturing. The active ester permits acylation of amino-functionalized polymers, dendrimers, and linker intermediates without the use of a coupling reagent in the final conjugation reactor. Z-Gln-OH is treated with 1.0–1.2 eq N-hydroxysuccinimide and 1.0–1.1 eq dicyclohexylcarbodiimide in anhydrous tetrahydrofuran or ethyl acetate at 0–5 °C, then stirred at 20–25 °C for 8–16 h. Precipitated dicyclohexylurea is removed by filtration through a pressure filter, and the filtrate is concentrated under reduced pressure below 40 °C to avoid thermal degradation of the Cbz chromophore and the unprotected primary amide. The resulting Z-Gln-OSu is moisture-sensitive and is stored at −20 °C under inert gas. Residual dicyclohexylurea and unreacted dicyclohexylcarbodiimide are monitored by HPLC and GC because both are potential sensitizers and must be controlled before the active ester is used in a cGMP conjugation step. For pentafluorophenyl ester formation, pentafluorophenol is substituted at 1.0–1.1 eq under the same solvent and temperature envelope. These Cbz-protected active esters are then coupled to amino-PEG chains, polylysine scaffolds, or diagnostic peptide linkers in anhydrous aprotic solvents at 5–25 °C, using 1.1–1.3 eq active ester per free amine. The terminal products are protected peptide conjugates that are subsequently hydrogenolysed to remove the Cbz group; the deprotected primary amine is then available for further chain extension or label attachment.

When Cbz-L-Glutamine Is Designated as a GMP Starting Material in Peptide Drug Substance Filing

When a peptide drug substance synthesis selects the Cbz protection route, CBZ-L-glutamine is often designated as a GMP starting material under ICH Q7, and the control strategy is described under ICH Q11. The cGMP release of the incoming protected amino acid includes acceptance tests for appearance, specific optical rotation, HPLC purity, residual solvents, water content, and residual palladium if the vendor process uses hydrogenolysis. Typical peptide-grade specifications include HPLC area percent purity NLT 99.0%, any unspecified impurity NMT 0.10%, chiral isomer NMT 0.5%, water content NMT 0.5% by USP <921>, sulfated ash NMT 0.1% by USP <281>, and residual solvents controlled according to ICH Q3C class 2 and class 3 limits. Residual palladium is controlled according to ICH Q3D, with a typical acceptance limit of NMT 10 ppm for parenteral peptide APIs unless justified by safety assessment. The certificate of analysis must include the analytical method designations for each test; HPLC purity by area percent does not by itself quantify mass balance, so assay by qNMR or titration against a qualified reference standard is often required. The terminal controlled product is the Cbz-protected Gln-containing peptide API intermediate, not the free amino acid itself; therefore the specification must also address process-related impurities that carry the Cbz chromophore and can co-elute under UV detection.

In custom peptide library manufacturing, CBZ-L-glutamine is used as a solution-phase fragment donor when a Cbz-protected Gln residue is needed at the N-terminus of a short oligopeptide that will later be coupled to a resin-bound sequence or a biotinylated probe. The process differs from routine solid-phase assembly with Fmoc-amino acids because the Cbz group is not removed by the standard 20% piperidine/DMF deprotection cycle used in Fmoc SPPS; this orthogonality is exploited to keep the Gln amino group protected while side-chain deprotections or on-resin modifications occur elsewhere in the sequence. Typical loading uses 1.5–2.0 eq CBZ-L-glutamine, 1.5–2.0 eq HATU or PyBOP, and 3.0–4.0 eq N,N-diisopropylethylamine in DMF for 45–60 min at 20–25 °C when coupling to a free amine on resin or in solution. The Cbz group is removed only after the Gln-containing fragment has been isolated, using hydrogenation or transfer hydrogenation; this late-stage deprotection minimizes exposure of the free N-terminus to subsequent acylation steps. Finished peptides are cleaved from resin with trifluoroacetic acid/triisopropylsilane/water mixtures and lyophilized. Terminal products include Gln-containing peptide probes for receptor binding, enzyme substrate profiling, and epitope mapping, where the Cbz route is selected because the protected fragment can be isolated and characterized as a discrete intermediate. Published data for this specific orthogonal strategy in large-scale peptide library production is limited compared with standard Fmoc/tBu SPPS; each contract manufacturing organization qualifies the coupling efficiency by Kaiser or chloranil test and HPLC monitoring.

Bulk Transfer and Solution-Phase Coupling in Peptide Contract Manufacturing

The bulk transfer of CBZ-L-glutamine into a coupling reactor in multi-kilogram peptide contract manufacturing is controlled under low relative humidity because the free carboxylic acid form is sufficiently polar to gain surface moisture. Pre-drying under vacuum at 35–40 °C for 4–8 h is applied when the incoming water content exceeds 0.5%; drying above 45 °C is avoided to reduce the risk of thermal degradation of the Cbz chromophore and the unprotected primary amide. The dried material is charged at 1.0–1.2 eq relative to the peptide fragment amine, dissolved in DMF or N-methyl-2-pyrrolidone, and activated with propylphosphonic anhydride in the presence of N-methylmorpholine. The process temperature is maintained at 0–10 °C for the exothermic coupling initiation, then raised to 20–25 °C for 2–6 h. In-process HPLC monitoring quantifies remaining CBZ-L-glutamine and the active ester intermediate; the coupling is judged complete when residual CBZ-L-glutamine is NMT 1.0% area. The reaction mass is then quenched with aqueous citric acid, extracted with ethyl acetate, and washed with saturated sodium bicarbonate and brine. The terminal product from this unit operation is the Cbz-protected Gln-containing peptide fragment in ethyl acetate solution, which is carried into hydrogenolysis without isolation in some campaigns to avoid thermal history. This contract manufacturing route is subject to ICH Q7, and the vessel train is dedicated or cleaned to prevent cross-contamination with palladium waste from the subsequent hydrogenolysis step.